Accum-T-deruxtecan

Accum-T-deruxtecan is a **preclinical Accum-modified antibody-drug conjugate program** from Defence Therapeutics in which the company applies its proprietary Accum intracellular delivery technology to **T-deruxtecan based HER2-directed ADC constructs**. The program was reported as a set of selected Accum variants designed to improve intracellular trafficking, promote endosomal escape and increase nuclear routing of the deruxtecan-containing ADC payload, thereby enhancing cytotoxic activity in **HER2-positive breast cancer** models, including trastuzumab- and T-DM1-resistant disease. In disclosed in vitro work, five Accum-T-deruxtecan variants increased potency by roughly five-fold versus the unmodified T-deruxtecan comparator in the JIMT-1 HER2-positive resistant breast cancer model. Mechanistically, the therapeutic concept remains that of a **HER2-targeted antibody-drug conjugate carrying a topoisomerase I inhibitor payload**, with Accum intended to improve subcellular delivery rather than change the underlying payload pharmacology.

Other names

Accum T-deruxtecanAccum variants combined with T-deruxtecanAccum-conjugated T-deruxtecan